三种新兴的免疫检查点分子在肿瘤免疫治疗中的研究进展  

Research progress of three emerging immune checkpoint molecules in tumor immunotherapy

作　　者：王成吕 聂玉洁 潘润桑 朱兰 陈双会 陈辉 张湘燕[1,2] 聂瑛洁 WANG Chenglyu;NIE Yujie;PAN Runsang;ZHU Lan;CHEN Shuanghui;CHEN Hui;ZHANG Xiangyan;NIE Yingjie(The Medical College,Guizhou University,Guizhou Guiyang 550025,China;Guizhou Provincial People's Hospital,Guizhou Guiyang 550002,China;Guiyang Children's Hospital,Guizhou Guiyang 550002,China)

机构地区：[1]贵州大学医学院,贵州贵阳550025 [2]贵州省人民医院,贵州贵阳550002 [3]贵阳市儿童医院,贵州贵阳550002

出　　处：《现代肿瘤医学》2022年第7期1308-1312,共5页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:82060308);贵州省科技计划项目(编号:黔科合平台人才[2018]5801,黔人领办发[2018]4号);中国医学科学院基金(编号:2019PT320003)。

摘　　要：免疫检查点作为体内的“刹车分子”,与肿瘤的增殖、侵袭、转移及患者预后评估紧密相关,是良好的肿瘤治疗靶点。现有的免疫检查点阻断剂在非小细胞肺癌、黑色素瘤等恶性肿瘤上表现出较好疗效,但随之而来的免疫治疗相关不良反应也很突出。因此,寻找新的免疫检查点分子成为近年的研究热点。B7族同源体3(B7 Homolog 3,B7-H3)、T细胞免疫球蛋白和ITIM域(T cell immunoglobulin and ITIM domain,TIGIT)、肿瘤坏死因子受体2(tumor necrosis factor receptor 2,TNFR2)作为新兴的免疫检查点分子在肿瘤免疫治疗领域备受瞩目,本文将对其分子特性及相关研究进展进行综述。Immune checkpoints,as brake molecules in the body,are closely related to tumor proliferation,invasion,metastasis and patient prognosis assessment,which are good tumor treatment targets.Existing immune checkpoint blockers have shown good curative effects on non-small cell lung cancer,melanoma and other malignant tumors,but the subsequent immunotherapy-related adverse reactions are also very prominent.Therefore,the searching for novel immune checkpoint have become a research hotspot in recent years.B7-H3(B7 Homolog 3),TIGIT(T cell immunoglobulin and ITIM domain)and TNFR2(tumor necrosis factor receptor 2)have attracted much attention in the field of immunotherapy as emerging immune checkpoint molecules.This article will review their molecular characteristics and related research progress.

关 键 词：B7族同源体3 T细胞免疫球蛋白和ITIM域 肿瘤坏死因子受体2 免疫检查点 

分 类 号：R730[医药卫生—肿瘤]